Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PHVS

Pharvaris NV

Jul 26 • 04:00PM ET

17.40

Dollar change -0.04
Percentage change -0.23	%

Healthcare • Biotechnology • Netherlands • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: SBIO BBC AVDS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.56	Insider Own	64.76%	Shs Outstand	52.29M	Perf Week	-5.23%
Market Cap	936.47M	Forward P/E	-	EPS next Y	-2.82	Insider Trans	0.00%	Shs Float	18.96M	Perf Month	-4.71%
Income	-115.13M	PEG	-	EPS next Q	-0.60	Inst Own	30.94%	Short Float	0.65%	Perf Quarter	-23.58%
Sales	0.00M	P/S	-	EPS this Y	12.30%	Inst Trans	-0.09%	Short Ratio	2.00	Perf Half Y	-41.04%
Book/sh	7.21	P/B	2.41	EPS next Y	-12.57%	ROA	-40.51%	Short Interest	0.12M	Perf Year	0.75%
Cash/sh	7.39	P/C	2.35	EPS next 5Y	20.59%	ROE	-43.59%	52W Range	15.00 - 33.00	Perf YTD	-37.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.27%	ROI	-29.67%	52W High	-47.27%	Beta	-3.05
Dividend TTM	-	Quick Ratio	20.53	Sales past 5Y	0.00%	Gross Margin	-	52W Low	16.00%	ATR (14)	1.25
Dividend Ex-Date	-	Current Ratio	20.53	EPS Y/Y TTM	-0.13%	Oper. Margin	0.00%	RSI (14)	44.18	Volatility	6.72% 6.83%
Employees	82	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.43	Target Price	33.56
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	21.19%	Payout	-	Rel Volume	0.57	Prev Close	17.44
Sales Surprise	-	EPS Surprise	6.79%	Sales Q/Q	-	Earnings	May 08 AMC	Avg Volume	62.05K	Price	17.40
SMA20	-3.15%	SMA50	-5.80%	SMA200	-20.98%	Trades		Volume	35,619	Change	-0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-25-23	Initiated	Wedbush	Outperform	$27
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$10 → $34
Oct-05-22	Initiated	Bryan Garnier	Buy	$16
Sep-13-22	Resumed	JMP Securities	Mkt Outperform	$34 → $18
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$40 → $10
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform	$26 → $13
May-25-22	Initiated	JMP Securities	Mkt Outperform	$34
Mar-02-21	Initiated	SVB Leerink	Outperform	$50
Mar-02-21	Initiated	Oppenheimer	Outperform	$48
Mar-02-21	Initiated	Morgan Stanley	Overweight	$51
Mar-02-21	Initiated	BofA Securities	Neutral	$41

Show Previous Ratings

Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
Jun-11-24 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-04-24 06:50AM	Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses (GlobeNewswire) -5.31%
May-13-24 06:50AM	Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses (GlobeNewswire)
11:55PM	Loading…
May-08-24 11:55PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 (InvestorPlace) -7.82%
04:10PM	Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-10-24 09:52PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
04:08PM	Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer (GlobeNewswire)
Apr-04-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference (GlobeNewswire)
Mar-18-24 06:50AM	Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses (GlobeNewswire) +6.34%
Mar-06-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses (GlobeNewswire) +5.86%
Mar-05-24 06:50AM	Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 (GlobeNewswire)
Feb-22-24 06:50AM	Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting (GlobeNewswire)
06:50AM	Loading…
Feb-16-24 06:50AM	Pharvaris Announces Extraordinary Meeting of Shareholders (GlobeNewswire)
Jan-26-24 06:50AM	Pharvaris to Present at the WSAAI Annual Meeting 2024 (GlobeNewswire)
Jan-23-24 09:34AM	Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program (Zacks)
Jan-22-24 04:07PM	Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision (Investor's Business Daily) +6.27%
07:34AM	FDA lifts remaining hold on Pharvaris' HAE drug, clearing path to phase 3 (FierceBiotech.com)
06:50AM	Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Jan-05-24 06:50AM	Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities (GlobeNewswire)
Dec-08-23 06:00PM	Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA LEN UCARE Conference 2023 (GlobeNewswire)
Dec-07-23 03:17PM	Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal (Zacks)
Dec-06-23 10:16AM	Why Is Pharvaris (PHVS) Stock Up 36% Today? (InvestorPlace) +18.14%
09:33AM	Pharvaris' oral hereditary angioedema med slashes attacks in turnaround post-FDA hold (FierceBiotech.com)
07:02AM	Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants (GlobeNewswire)
06:56AM	Pharvaris shares spike as drug appears to prevent symptoms of rare disorder (BioPharma Dive)
06:50AM	Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Nov-30-23 06:50AM	Pharvaris to Present at the GA LEN UCARE Conference 2023 (GlobeNewswire)
06:50AM	Loading…
Nov-15-23 06:50AM	Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer (GlobeNewswire) -11.49%
Nov-09-23 11:00AM	Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Nov-02-23 06:50AM	Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 06:50AM	Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Oct-13-23 06:50AM	Pharvaris To Present at the APAAACI 2023 International Conference (GlobeNewswire)
Oct-04-23 07:34AM	Pharvaris To Present at the CIIC Fall 2023 Conference (GlobeNewswire)
Sep-19-23 06:50AM	Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) +16.68%
Sep-06-23 06:51AM	Pharvaris To Present at the 18th German Allergy Congress (GlobeNewswire)
06:50AM	Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-31-23 08:09PM	Expect at Least 60% Upside, Says Morgan Stanley About These 2 Buy-Rated Stocks (TipRanks)
Aug-23-23 06:50AM	Pharvaris To Present at the 2023 HAEi Regional Conference EMEA (GlobeNewswire)
Aug-15-23 09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly) +8.58%
Aug-07-23 06:50AM	Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.91%
Jul-21-23 10:20AM	Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit (GlobeNewswire)
Jul-03-23 08:16AM	Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 50% ownership, institutions own 18% (Simply Wall St.)
Jun-27-23 12:11PM	Why Shares of Pharvaris N.V. Are Up Tuesday (Motley Fool) +7.96%
Jun-26-23 02:27PM	FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE (Benzinga) +27.76%
06:50AM	Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE (GlobeNewswire)
Jun-20-23 06:50AM	Pharvaris Announces $70 Million Private Placement Financing (GlobeNewswire)
Jun-10-23 06:01PM	Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023 (GlobeNewswire)
Jun-01-23 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire) +5.12%
May-17-23 09:55AM	Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know (Zacks)
May-08-23 06:50AM	Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-06-23 01:00PM	Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop (GlobeNewswire)
Apr-05-23 06:51AM	Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-23 03:31PM	We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth (Simply Wall St.) -5.11%
Mar-18-23 12:35AM	Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC (GlobeNewswire)
Mar-02-23 06:50AM	Pharvaris to Present in Upcoming March Investor Conferences (GlobeNewswire) +8.51%
Feb-24-23 06:50AM	Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting (GlobeNewswire) -9.25%
Feb-08-23 06:50AM	Pharvaris to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-24-23 05:36AM	Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 44% ownership, institutions own 26% (Simply Wall St.) +6.42%
Jan-09-23 06:50AM	Pharvaris Provides Regulatory, Clinical, and Corporate Updates (GlobeNewswire)
Dec-08-22 01:15PM	Pharvaris Shares Surges On Positive Data From HAE Attacks Study, Makes Way For FDA To Remove Clinical Hold (Benzinga) +356.57%
06:51AM	Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
06:50AM	Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks (GlobeNewswire)
Nov-10-22 08:00AM	Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022 (GlobeNewswire) -10.32%
Oct-11-22 02:27PM	We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely (Simply Wall St.) -5.48%
Oct-07-22 08:30AM	Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop (GlobeNewswire) -10.12%
Sep-30-22 06:50AM	Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer (GlobeNewswire)
Sep-16-22 04:45AM	Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium (GlobeNewswire)
Sep-12-22 06:50AM	Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-22-22 04:09PM	Why Pharvaris Stock Crashed And Why At Least One Analyst Isn't Worried (Investor's Business Daily) -34.32% -9.51%
03:45PM	Why Pharvaris Shares Are Plummeting Today? (Benzinga)
06:50AM	Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S. (GlobeNewswire)
Jul-14-22 08:10AM	Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference (GlobeNewswire)
Jul-06-22 08:10AM	Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13 (GlobeNewswire)
Jun-14-22 08:10AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-07-22 08:10AM	Pharvaris Participates in the Kinin 2022 Conference (GlobeNewswire) +9.14%
May-16-22 08:10AM	Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-) (GlobeNewswire)
May-11-22 08:15AM	Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer (GlobeNewswire)
08:10AM	Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire)
May-05-22 04:10PM	Pharvaris to Participate in BofA Securities 2022 Healthcare Conference (GlobeNewswire)
May-04-22 01:14PM	Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth (Simply Wall St.)
Apr-06-22 04:10PM	Pharvaris to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-29-22 08:10AM	Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-22-22 08:10AM	Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology (GlobeNewswire)
Mar-03-22 08:00AM	Pharvaris to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-25-22 09:40AM	Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-09-22 08:10AM	Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-26-22 09:40AM	Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-22-21 08:10AM	Pharvaris Announces Changes to its Board of Directors (GlobeNewswire)
Dec-07-21 08:10AM	Pharvaris Announces Changes to its Board of Directors (GlobeNewswire)
Nov-10-21 08:10AM	Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-08-21 05:51AM	7 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global (Insider Monkey) +6.26%
Nov-02-21 02:00PM	We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely (Simply Wall St.) -8.46%
Sep-03-21 08:00AM	Pharvaris to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Jul-30-21 08:00AM	Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights (GlobeNewswire) +5.15%
Jul-09-21 06:10PM	Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 (GlobeNewswire) +5.89% +8.91%
Jul-01-21 07:00AM	Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 (GlobeNewswire) -6.44%
Jun-11-21 08:00AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHVS

Pharvaris NV

Upgrade your FINVIZ experience